LBP for COPD
Chronic Obstructive Pulmonary Disease (COPD)
Key Facts
About Alveolus Bio
Alveolus Bio is an early-stage biotech developing first-in-class inhaled live biotherapeutics for chronic respiratory diseases. The company's core innovation is the resMIT platform, designed for targeted pulmonary delivery of bacteria to modulate the lung microbiome and treat underlying disease mechanisms like fibroblast dysfunction and inflammation. With a strong, interdisciplinary team and a preclinical pipeline targeting high-need indications such as IPF and COPD, Alveolus Bio is positioned to pursue a novel therapeutic approach in a field dominated by small molecules and biologics. The company is privately held, pre-revenue, and actively seeking investment and partnerships to advance its programs.
View full company profileTherapeutic Areas
Other Chronic Obstructive Pulmonary Disease (COPD) Drugs
| Drug | Company | Phase |
|---|---|---|
| PUR0200 | Pulmatrix | Preclinical |
| Dupixent (dupilumab) | Regeneron | Phase 3 |
| REGEND001 | Regend | Phase 1 |
| COPD Trial | Well Pharma Medical Research | Not Specified |
| AN01 | AirNexis Therapeutics | Phase 2 |
| COPD Diagnostic/Prognostic Test | Oxford Cancer Analytics | Pre-clinical |
| SMS Cell Therapy | SMSbiotech | Phase 1b |
| dNerva Lung Denervation System / Targeted Lung Denervation (TLD) | Nuvaira | Phase 3 |
| AstraZeneca Collaboration Programs | Ethris | Discovery/Pre-clinical |
| COPD Phenotyping & Progression Biomarkers | Thirona | Commercial/Validation |
| TEZSPIRE (tezepelumab) | Amgen | Phase 3 |
| Verekitug (UPB-101) | Upstream Bio | Phase 2 |